var docs;if (!docs) docs =[]; docs["103"]={"10300":"<p><b>Title</b> Potassium Chloride / Glycopyrrolate (Systemic)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: Use of solid oral dosage forms of potassium chloride are contraindicated with glycopyrrolate.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Glycopyrrolate (Systemic) may enhance the adverse/toxic effect of Potassium Chloride. This is specific to solid oral dosage forms of potassium chloride. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of solid oral dosage forms of potassium chloride are contraindicated with glycopyrrolate. Consider using a non-solid oral dosage form or another alternative therapy as appropriate.</p> \n<p><b>Discussion</b> According to glycopyrrolate prescribing information, concurrent use with solid oral dosage forms of potassium chloride is contraindicated.<sup>1</sup> Due to the significant anticholinergic effects of glycopyrrolate there are concerns that the passage of the potassium chloride solid dosage form through the gastrointestinal tract could be impaired with concurrent use.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Cuvposa (glycopyrrolate). Atlanta, GA: Mikart Inc; November 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10301":"<p><b>Title</b> Sodium Stibogluconate / Amphotericin B (Conventional)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Amphotericin B (Conventional) may enhance the cardiotoxic effect of Sodium Stibogluconate. Specifically, arrhythmia and sudden cardiac death risks may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider separating courses of sodium stibogluconate and amphotericin B deoxycholate by 14 days or more. Correct electrolyte imbalances before transitioning patients from sodium stibogluconate to amphotericin B deoxycholate, and closely monitor cardiac status.</p> \n<p><b>Discussion</b> The sodium stibogluconate UK summary of product characteristics states that an increased risk of fatal cardiac arrhythmias has been described in patients with visceral leishmaniasis receiving amphotericin B soon after sodium stibogluconate.<sup>1</sup> A published case series describes 3 patients 5-7 years of age with visceral leishmaniasis who experienced sudden cardiac death after amphotericin B deoxycholate was initiated within 2 weeks of stopping sodium stibogluconate treatment.<sup>2</sup> In a clinical trial of amphotericin use in patients with myocardial damage attributed to sodium antimony gluconate, 3 of 7 patients receiving amphotericin B soon after sodium antimony gluconate termination developed cardiac arrhythmias and cardiac arrest.<sup>3</sup> Two of these patients died. In contrast, 69 patients who received amphotericin B 10 days after sodium antimony gluconate termination recovered without cardiac events, including the patient who survived cardiac arrest on the other regimen. <br><br>The mechanism of the possible interaction between these agents interaction has not been established.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Pentostam (sodium stibogluconate) [summary of product characteristics]. Middlesex, United Kingdom: The Wellcome Foundation Ltd; February 2014.</p>\n<p>2. Maheshwari A, Seth A, Kaur S, et al. Cumulative cardiac toxicity of sodium stibogluconate and amphotericin B in treatment of kala-azar. <i>Pediatr Infect Dis J</i>. 2011;30(2):180-181. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20823781\">[PubMed 20823781]</a></p>\n<p>3. Thakur CP. Sodium antimony gluconate, amphotericin, and myocardial damage. <i>Lancet</i>. 1998;351(9120):1928-1929. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9654264\">[PubMed 9654264]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10302":"<p><b>Title</b> Sodium Stibogluconate / Amphotericin B</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Amphotericin B may enhance the cardiotoxic effect of Sodium Stibogluconate. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider separating courses of sodium stibogluconate and amphotericin B deoxycholate by 14 days or more. Correct electrolyte imbalances before transitioning patients from sodium stibogluconate to amphotericin B deoxycholate, and closely monitor cardiac status.</p>\n<div>\n <p><b>Amphotericin B Interacting Members</b> Amphotericin B (Conventional), Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex</p>\n</div> \n<p><b>Discussion</b> The sodium stibogluconate UK summary of product characteristics states that an increased risk of fatal cardiac arrhythmias has been described in patients with visceral leishmaniasis receiving amphotericin B soon after sodium stibogluconate.<sup>1</sup> A published case series describes 3 patients 5-7 years of age with visceral leishmaniasis who experienced sudden cardiac death after amphotericin B deoxycholate was initiated within 2 weeks of stopping sodium stibogluconate treatment.<sup>2</sup> In a clinical trial of amphotericin use in patients with myocardial damage attributed to sodium antimony gluconate, 3 of 7 patients receiving amphotericin B soon after sodium antimony gluconate termination developed cardiac arrhythmias and cardiac arrest.<sup>3</sup> Two of these patients died. In contrast, 69 patients who received amphotericin B 10 days after sodium antimony gluconate termination recovered without cardiac events, including the patient who survived cardiac arrest on the other regimen. <br><br>The mechanism of the possible interaction between these agents interaction has not been established.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Pentostam (sodium stibogluconate) [summary of product characteristics]. Middlesex, United Kingdom: The Wellcome Foundation Ltd; February 2014.</p>\n<p>2. Maheshwari A, Seth A, Kaur S, et al. Cumulative cardiac toxicity of sodium stibogluconate and amphotericin B in treatment of kala-azar. <i>Pediatr Infect Dis J</i>. 2011;30(2):180-181. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20823781\">[PubMed 20823781]</a></p>\n<p>3. Thakur CP. Sodium antimony gluconate, amphotericin, and myocardial damage. <i>Lancet</i>. 1998;351(9120):1928-1929. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9654264\">[PubMed 9654264]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10303":"<p><b>Title</b> Eszopiclone / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eszopiclone. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Limit the eszopiclone dose to 2 mg daily when combined with strong CYP3A4 inhibitors and monitor for increased eszopiclone effects and toxicities (eg, somnolence, drowsiness, CNS depression).</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in eszopiclone product labeling, ketoconazole (400 mg daily x 5 days) increased the eszopiclone (3 mg single dose) AUC, maximum serum concentration, and half-life 2.2-fold, 1.4-fold, and 1.3-fold, respectively.<sup>1,2</sup><br><br>Product labeling recommends limiting the dose of eszopiclone to 2 mg daily when combined with strong CYP3A4 inhibitors.<sup>1,2</sup><br><br>The mechanism of this interaction is likely ketoconazole inhibition of CYP3A4, an enzyme responsible for eszopiclone metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lunesta (eszopiclone) [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc; May 2014.</p>\n<p>2. Lunesta (eszopiclone) [product monograph]. Mississauga, Ontario, Canada: Sunovion Pharmaceuticals Canada Inc; March 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10304":"<p><b>Title</b> Tenofovir Alafenamide / Tipranavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Tipranavir may decrease the serum concentration of Tenofovir Alafenamide. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of tipranavir/ritonavir and tenofovir alafenamide.</p> \n<p><b>Discussion</b> Prescribing information for the emtricitabine/tenofovir alafenamide combination product states that concomitant use with tipranavir/ritonavir should be avoided due to the risk for decreased tenofovir alafenamide concentrations, reduced efficacy, and development of resistance.<sup>1</sup> The emtricitabine/rilpivirine/tenofovir alafenamide and elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide combination products should not be combined with tipranavir since they are complete stand-alone HIV regimens.<sup>2,3</sup><br><br>The mechanism of this potential interaction has not been investigated and is not stated in the prescribing information. Tipranavir/ritonavir induction of P-glycoprotein, a transporter involved in tenofovir alafenamide disposition, may play a role.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Descovy (emtricitabine/tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; April 2016.</p>\n<p>2. Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; March 2016.</p>\n<p>3. Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; March 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10305":"<p><b>Title</b> Tenofovir Alafenamide / CarBAMazepine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: The management of this interaction differs when tenofovir alafenamide is used as monotherapy for the treatment of hepatitis B virus infection versus when tenofovir alafenamide is used in combination with antiretroviral agents for the treatment of HIV.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Tenofovir Alafenamide. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> When tenofovir alafenamide is combined with antiretrovirals for the treatment of HIV, the concomitant use of carbamazepine and tenofovir alafenamide should be avoided. Carbamazepine is contraindicated with the emtricitabine/rilpivirine/tenofovir alafenamide and elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide combination products.<br><br>When tenofovir alafenamide is used as monotherapy for the treatment of hepatitis B virus infection, increase the tenofovir alafenamide dose to 50 mg (2 tablets) daily if combined with carbamazepine.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the tenofovir alafenamide prescribing information, carbamazepine (300 mg twice daily) combined with emtricitabine/tenofovir alafenamide (200 mg/25 mg daily) decreased the tenofovir alafenamide AUC and maximum serum concentration 55% and 57%, respectively.<sup>1,2</sup><br><br>According to the prescribing information for tenofovir alafenamide containing products, concomitant use with carbamazepine may result in reduced tenofovir alafenamide concentrations and lead to decreased efficacy or the development of resistance.<sup>1,2,3,4,5</sup> The emtricitabine/rilpivirine/tenofovir alafenamide and elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide combination products list use with carbamazepine as contraindicated.<sup>3,4</sup> The emtricitabine/tenofovir alafenamide and the bictegravir/emtricitabine/tenofovir alafenamide products recommend selecting an alternative anticonvulsant.<sup>2,5</sup> When used as monotherapy for the treatment of hepatitis B virus infection, the tenofovir alafenamide dose should be increased to 50 mg daily (2 tablets) when combined with carbamazepine.<sup>1</sup><br><br>The mechanism of this potential interaction has not been investigated, but carbamazepine induction of P-glycoprotein, a transporter involved in tenofovir alafenamide disposition, may play a role.<sup>1,2,3,4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Vemlidy (tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; April 2017.</p>\n<p>2. Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; February 2018.</p>\n<p>3. Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; March 2016.</p>\n<p>4. Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; March 2016.</p>\n<p>5. Descovy (emtricitabine/tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; April 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10306":"<p><b>Title</b> Tenofovir Alafenamide / Fosphenytoin-Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Fosphenytoin-Phenytoin may decrease the serum concentration of Tenofovir Alafenamide. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the concomitant use of fosphenytoin or phenytoin with tenofovir alafenamide. Phenytoin is contraindicated with the emtricitabine/rilpivirine/tenofovir alafenamide and elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide combination products.</p>\n<div>\n <p><b>Fosphenytoin-Phenytoin Interacting Members</b> Fosphenytoin, Phenytoin</p>\n</div> \n<p><b>Discussion</b> According to the prescribing information for tenofovir alafenamide containing products, concomitant use with phenytoin may result in reduced tenofovir alafenamide concentrations and lead to decreased efficacy or the development of resistance.<sup>1,2</sup> The emtricitabine/rilpivirine/tenofovir alafenamide and elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide combination products list use with phenytoin as contraindicated.<sup>2,3</sup> The emtricitabine/tenofovir alafenamide product recommends selecting an alternative anticonvulsant.<sup>1</sup><br><br>The mechanism of this potential interaction has not been investigated and is not stated in the prescribing information. Phenytoin induction of P-glycoprotein, a transporter involved in tenofovir alafenamide disposition, may play a role.<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Descovy (emtricitabine/tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; April 2016.</p>\n<p>2. Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; March 2016.</p>\n<p>3. Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; March 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10307":"<p><b>Title</b> Tenofovir Alafenamide / PHENobarbital</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> PHENobarbital may decrease the serum concentration of Tenofovir Alafenamide. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the concomitant use of phenobarbital with tenofovir alafenamide. Phenobarbital is contraindicated with the emtricitabine/rilpivirine/tenofovir alafenamide and elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide combination products.</p> \n<p><b>Discussion</b> According to the prescribing information for tenofovir alafenamide containing products, concomitant use with phenobarbital may result in reduced tenofovir alafenamide concentrations and lead to decreased efficacy or the development of resistance.<sup>1,2</sup> The emtricitabine/rilpivirine/tenofovir alafenamide and elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide combination products list use with phenobarbital as contraindicated.<sup>2,3</sup> The emtricitabine/tenofovir alafenamide product recommends selecting an alternative anticonvulsant.<sup>1</sup><br><br>The mechanism of this potential interaction has not been investigated and is not stated in the prescribing information. Phenobarbital induction of P-glycoprotein, a transporter involved in tenofovir alafenamide disposition, may play a role.<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Descovy (emtricitabine/tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; April 2016.</p>\n<p>2. Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; March 2016.</p>\n<p>3. Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; March 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10308":"<p><b>Title</b> Tenofovir Alafenamide / Primidone</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Primidone may decrease the serum concentration of Tenofovir Alafenamide. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the concomitant use of primidone with tenofovir alafenamide. Phenobarbital (the active moiety of the prodrug primidone) is contraindicated with the emtricitabine/rilpivirine/tenofovir alafenamide and elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide combination products.</p> \n<p><b>Discussion</b> According to the prescribing information for tenofovir alafenamide containing products, concomitant use with phenobarbital may result in reduced tenofovir alafenamide concentrations and lead to decreased efficacy or the development of resistance.<sup>1,2</sup> The emtricitabine/rilpivirine/tenofovir alafenamide and elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide combination products list use with phenobarbital as contraindicated.<sup>2,3</sup> The emtricitabine/tenofovir alafenamide product recommends selecting an alternative anticonvulsant.<sup>1</sup><br><br>The mechanism of this potential interaction has not been investigated and is not stated in the prescribing information. Phenobarbital induction of P-glycoprotein, a transporter involved in tenofovir alafenamide disposition, may play a role.<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Descovy (emtricitabine/tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; April 2016.</p>\n<p>2. Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; March 2016.</p>\n<p>3. Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; March 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10309":"<p><b>Title</b> Tenofovir Alafenamide / OXcarbazepine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> OXcarbazepine may decrease the serum concentration of Tenofovir Alafenamide. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the concomitant use of oxcarbazepine and tenofovir alafenamide. Oxcarbazepine is contraindicated with the emtricitabine/rilpivirine/tenofovir alafenamide combination product.</p> \n<p><b>Discussion</b> According to the prescribing information for tenofovir alafenamide containing products, concomitant use with oxcarbazepine may result in reduced tenofovir alafenamide concentrations and lead to decreased efficacy or the development of resistance.<sup>1,2</sup> The emtricitabine/rilpivirine/tenofovir alafenamide combination product lists use with oxcarbazepine as contraindicated.<sup>2</sup> The emtricitabine/tenofovir alafenamide and the elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide combination products recommend selecting an alternative anticonvulsant.<sup>1,3</sup><br><br>The mechanism of this potential interaction has not been investigated and is not stated in the prescribing information. Tenofovir alafenamide is a P-glycoprotein (P-gp) substrate and although the structurally related drug carbamazepine is thought to induce P-gp, oxcarbazepine has not been shown to induce P-gp.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Descovy (emtricitabine/tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; April 2016.</p>\n<p>2. Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; March 2016.</p>\n<p>3. Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; March 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10310":"<p><b>Title</b> Tenofovir Alafenamide / Rifabutin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Rifabutin may decrease the serum concentration of Tenofovir Alafenamide. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the concomitant use of rifabutin and tenofovir alafenamide.</p> \n<p><b>Discussion</b> According to the prescribing information for tenofovir alafenamide containing products, concomitant use with rifabutin may result in reduced tenofovir alafenamide concentrations and lead to decreased efficacy or the development of resistance.<sup>1,2,3</sup> Avoidance of this combination is recommended.<sup>1,2,3</sup><br><br>The mechanism of this potential interaction has not been investigated and is not stated in the prescribing information. Rifabutin induction of P-glycoprotein (P-gp), a transporter involved in tenofovir alafenamide disposition, may play a role, but data to suggest that rifabutin is a clinically relevant P-gp inducer is limited<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Descovy (emtricitabine/tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; April 2016.</p>\n<p>2. Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; March 2016.</p>\n<p>3. Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; March 2016.</p>\n<p>4. Williamson B, Dooley KE, Zhang Y, Back DJ, Owen A. Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine. <i>Antimicrob Agents Chemother</i>. 2013;57(12):6366-6369. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24060875\">[PubMed 24060875]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10311":"<p><b>Title</b> Tenofovir Alafenamide / Rifapentine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Rifapentine may decrease the serum concentration of Tenofovir Alafenamide. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the concomitant use of rifapentine and tenofovir alafenamide. Rifapentine is contraindicated with the emtricitabine/rilpivirine/tenofovir alafenamide combination product.</p> \n<p><b>Discussion</b> According to the prescribing information for tenofovir alafenamide containing products, concomitant use with rifapentine may result in reduced tenofovir alafenamide concentrations and lead to decreased efficacy or the development of resistance.<sup>1,2</sup> The emtricitabine/rilpivirine/tenofovir alafenamide combination product lists use with rifapentine as contraindicated.<sup>2</sup> The emtricitabine/tenofovir alafenamide and the elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide combination products recommend avoiding use with rifapentine.<sup>1,3</sup><br><br>The mechanism of this potential interaction has not been investigated and is not stated in the prescribing information. Rifapentine induction of P-glycoprotein (P-gp), a transporter involved in tenofovir alafenamide disposition, may play a role, but data to suggest that rifapentine is a clinically relevant P-gp inducer is limited<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Descovy (emtricitabine/tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; April 2016.</p>\n<p>2. Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; March 2016.</p>\n<p>3. Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; March 2016.</p>\n<p>4. Williamson B, Dooley KE, Zhang Y, Back DJ, Owen A. Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine. <i>Antimicrob Agents Chemother</i>. 2013;57(12):6366-6369. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24060875\">[PubMed 24060875]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10312":"<p><b>Title</b> Tenofovir Alafenamide / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Tenofovir Alafenamide. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the concomitant use of rifampin and tenofovir alafenamide. Rifampin is contraindicated with the emtricitabine/rilpivirine/tenofovir alafenamide and elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide combination products.</p> \n<p><b>Discussion</b> According to the prescribing information for tenofovir alafenamide containing products, concomitant use with rifampin may result in reduced tenofovir alafenamide concentrations and lead to decreased efficacy or the development of resistance.<sup>1,2</sup> The emtricitabine/rilpivirine/tenofovir alafenamide and elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide combination products list use with rifampin as contraindicated.<sup>2,3</sup> The emtricitabine/tenofovir alafenamide product recommends avoiding use with rifampin.<sup>1</sup><br><br>The mechanism of this potential interaction has not been investigated and is not stated in the prescribing information. Rifampin induction of P-glycoprotein, a transporter involved in tenofovir alafenamide disposition, may play a role.<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Descovy (emtricitabine/tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; April 2016.</p>\n<p>2. Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; March 2016.</p>\n<p>3. Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; March 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10313":"<p><b>Title</b> Tenofovir Alafenamide / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Tenofovir Alafenamide. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of St John's wort and tenofovir alafenamide. St John's wort is contraindicated with the emtricitabine/rilpivirine/tenofovir alafenamide and elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide combination products.</p> \n<p><b>Discussion</b> According to the prescribing information for tenofovir alafenamide containing products, concomitant use with St Johns wort may result in reduced tenofovir alafenamide concentrations and lead to decreased efficacy or the development of resistance.<sup>1,2</sup> The emtricitabine/rilpivirine/tenofovir alafenamide and elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide combination products list use with St Johns wort as contraindicated.<sup>2,3</sup> The emtricitabine/tenofovir alafenamide product recommends avoiding use with St Johns wort.<sup>1</sup><br><br>The mechanism of this potential interaction has not been investigated and is not stated in the prescribing information. St Johns wort induction of P-glycoprotein, a transporter involved in tenofovir alafenamide disposition, may play a role.<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Descovy (emtricitabine/tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; April 2016.</p>\n<p>2. Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; March 2016.</p>\n<p>3. Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; March 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10314":"<p><b>Title</b> Warfarin / Ezetimibe</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Ezetimibe may enhance the anticoagulant effect of Warfarin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a clinical study summarized in ezetimibe US prescribing information, coadministration of ezetimibe (10 mg daily for 11 days) caused minor (less than 5%) increases in maximum concentration and decreases in AUC of warfarin (25 mg single dose) enantiomers.<sup>1</sup> In a retrospective observational cohort analysis of 101 warfarin-treated patients, initiation of ezetimibe was associated with an average 12% increase in INR between the day of ezetimibe prescription and the next follow-up appointment (an average of 53 days later).<sup>2</sup> Individual changes ranged from approximately a halving of INR to approximately a doubling.<sup>2</sup> Similar findings from a second observational cohort analysis of 42 warfarin-treated patients are briefly summarized in another report.<sup>3</sup><br><br>Potential mechanisms of interaction between ezetimibe and warfarin have not been fully investigated. One potential mechanism by which ezetimibe could indirectly enhance anticoagulant effects is via inhibition of Niemann-Pick C1-like protein 1 (NPC1L1)-mediated gastrointestinal vitamin K uptake.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Zetia (ezetimibe) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; September 2014.</p>\n<p>2. Hashikata T, Yamaoka-Tojo M, Kakizaki R, et al. Ezetimibe enhances and stabilizes anticoagulant effect of warfarin [published online April 6, 2016]. <i>Heart Vessels</i>. doi: 10.1007/s00380-016-0832-z. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27052207\">[PubMed 27052207]</a></p>\n<p>3. Takada T, Yamanashi Y, Konishi K, et al. NPC1L1 is a key regulator of intestinal vitamin K absorption and a modulator of warfarin therapy. <i>Sci Transl Med</i>. 2015;7(275):275ra23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25696002\">[PubMed 25696002]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10315":"<p><b>Title</b> Venetoclax / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Venetoclax. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Strong CYP3A4 inhibitor use is contraindicated during venetoclax initiation and ramp-up. In patients receiving steady venetoclax doses after completion of the ramp-up phase, reduce the venetoclax dose by at least 75% if concomitant use of a strong CYP3A4 inhibitor is required. Monitor patients receiving these combinations closely for evidence of excessive venetoclax effects (eg, hematologic toxicity, tumor lysis syndrome). Resume the previous venetoclax dose 2 to 3 days after strong CYP3A4 inhibitor discontinuation.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic)*, Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir*, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a clinical study summarized in venetoclax US prescribing information, coadministration of the strong CYP3A4 inhibitors ketoconazole (400 mg daily) or ritonavir (50 mg once daily) increased the maximum concentration and AUC of venetoclax by 2.3- to 2.4-fold and 6.4- to 7.9-fold, respectively.<sup>1</sup> The suspected primary mechanisms of this interaction are inhibition of CYP3A4-mediated metabolism and P-glycoprotein-mediated efflux of venetoclax.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Venclexta (venetoclax) [prescribing information]. North Chicago, IL: AbbVie Inc; December 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10316":"<p><b>Title</b> Venetoclax / CYP3A4 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Venetoclax. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Reduce the venetoclax dose by at least 50% in patients requiring concomitant treatment with moderate CYP3A4 inhibitors. Monitor patients receiving these combinations closely for evidence of excessive venetoclax effects (eg, hematologic toxicity, tumor lysis syndrome). Resume the previous venetoclax dose 2 to 3 days after moderate CYP3A4 inhibitor discontinuation.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> In a clinical study summarized in venetoclax US prescribing information, coadministration of the strong CYP3A4 inhibitor and P-glycoprotein inhibitor ketoconazole (400 mg daily) increased the maximum concentration and AUC of venetoclax by 2.3- and 6.4-fold, respectively.<sup>1</sup> The suspected primary mechanisms of this interaction are ketoconazole inhibition of CYP3A4-mediated metabolism and P-glycoprotein-mediated efflux of venetoclax. Clinical data characterizing the impact of moderate CYP3A4 inhibitors on venetoclax exposure are not available. Venetoclax prescribing information recommends avoiding use with moderate CYP3A4 inhibitors when possible, and reducing the venetoclax dose by at least 50% when concomitant use cannot be avoided.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Venclexta (venetoclax) [prescribing information]. North Chicago, IL: AbbVie Inc; April 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10317":"<p><b>Title</b> Venetoclax / P-glycoprotein/ABCB1 Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Venetoclax. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Reduce the venetoclax dose by at least 50% in patients requiring concomitant treatment with P-glycoprotein inhibitors. Monitor patients receiving these combinations closely for evidence of excessive venetoclax effects (eg, hematologic toxicity, tumor lysis syndrome). Resume the previous venetoclax dose 2 to 3 days after P-glycoprotein inhibitor discontinuation.</p>\n<div>\n <p><b>P-glycoprotein/ABCB1 Inhibitors Interacting Members</b> Amiodarone, Azithromycin (Systemic), Carvedilol, Clarithromycin, CycloSPORINE (Systemic), Daclatasvir, Dronedarone, Eliglustat, Erythromycin (Systemic), Flibanserin, Glecaprevir and Pibrentasvir, Itraconazole, Ivacaftor, Ketoconazole (Systemic), Lapatinib, Ledipasvir, Neratinib, Ombitasvir, Paritaprevir, and Ritonavir, Propafenone, QuiNIDine, QuiNINE, Ranolazine, Ritonavir, Rolapitant, Simeprevir, Telaprevir, Velpatasvir, Vemurafenib, Verapamil</p>\n</div> \n<p><b>Discussion</b> In a clinical study summarized in venetoclax US prescribing information, coadministration of a single dose of rifampin (600 mg) increased the maximum concentration and AUC of venetoclax by 2.1- and 1.8-fold, respectively.<sup>1,2</sup> The suspected primary mechanism of this interaction is rifampin inhibition of P-glycoprotein-mediated efflux of venetoclax.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Venclexta (venetoclax) [prescribing information]. North Chicago, IL: AbbVie Inc; April 2016.</p>\n<p>2. Agarwal SK, Hu B, Chien D, Wong SL, Salem AH. Evaluation of rifampin's transporter inhibitory and CYP3A inductive effects on the pharmacokinetics of venetoclax, a Bcl-2 inhibitor: Results of a single- and multiple-dose study [published online March 7, 2016]. <i>J Clin Pharmacol</i>. doi: 10.1002/jcph.730. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26953185\">[PubMed 26953185]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10318":"<p><b>Title</b> Venetoclax / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Venetoclax. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of strong CYP3A4 inducers with venetoclax.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a clinical study summarized in venetoclax US prescribing information, coadministration of rifampin (600 mg daily for 13 days) decreased the maximum concentration and AUC of venetoclax by 42% and 71%, respectively.<sup>1,2</sup> The suspected primary mechanism of this interaction is rifampin induction of CYP3A4-mediated venetoclax metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Venclexta (venetoclax) [prescribing information]. North Chicago, IL: AbbVie Inc; April 2016.</p>\n<p>2. Agarwal SK, Hu B, Chien D, Wong SL, Salem AH. Evaluation of rifampin's transporter inhibitory and CYP3A inductive effects on the pharmacokinetics of venetoclax, a Bcl-2 inhibitor: Results of a single- and multiple-dose study [published online March 7, 2016]. <i>J Clin Pharmacol</i>. doi: 10.1002/jcph.730. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26953185\">[PubMed 26953185]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10319":"<p><b>Title</b> Venetoclax / CYP3A4 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Moderate) may decrease the serum concentration of Venetoclax. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of moderate CYP3A4 inducers with venetoclax.</p>\n<div>\n <p><b>CYP3A4 Inducers (Moderate) Interacting Members</b> Bexarotene (Systemic), Bosentan, Dabrafenib, Efavirenz, Eslicarbazepine, Etravirine, Modafinil, Nafcillin, Rifapentine, St John's Wort</p>\n</div> \n<p><b>Discussion</b> In a clinical study summarized in venetoclax US prescribing information, coadministration of the strong CYP3A4 inducer rifampin (600 mg daily for 13 days) decreased the maximum concentration and AUC of venetoclax by 42% and 71%, respectively.<sup>1</sup> The suspected primary mechanism of this interaction is rifampin induction of CYP3A4-mediated venetoclax metabolism. Clinical data characterizing the impact of moderate CYP3A4 inhibitors on venetoclax exposure are not available. Venetoclax prescribing information recommends avoiding use with strong or moderate CYP3A4 inducers.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Venclexta (venetoclax) [prescribing information]. North Chicago, IL: AbbVie Inc; April 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10320":"<p><b>Title</b> Warfarin / Venetoclax</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Venetoclax may increase the serum concentration of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor INR closely in patients receiving warfarin and venetoclax.</p> \n<p><b>Discussion</b> In a clinical study summarized in venetoclax US prescribing information, coadministration of a single venetoclax dose (400 mg) increased the maximum concentration and AUC of R- and S-warfarin enantiomers (following a 5 mg single dose of the racemate) by 18% to 28%.<sup>1</sup> The mechanism of this interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Venclexta (venetoclax) [prescribing information]. North Chicago, IL: AbbVie Inc; April 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10321":"<p><b>Title</b> Digoxin / Venetoclax</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction is only anticipated with oral/enteral digoxin.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Venetoclax may increase the serum concentration of Digoxin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Administer digoxin at least 6 hours before venetoclax when concomitant therapy is required.</p> \n<p><b>Discussion</b> Venetoclax US prescribing information states that use with certain P-glycoprotein substrates (digoxin, everolimus, and sirolimus) should be avoided if possible, based on in vitro inhibition studies that suggest a potential for venetoclax to inhibit intestinal P-glycoprotein-mediated efflux.<sup>1</sup> If concomitant therapy is required, prescribing information recommends that these P-glycoprotein substrates be administered at least 6 hours prior to venetoclax to minimize the potential for an interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Venclexta (venetoclax) [prescribing information]. North Chicago, IL: AbbVie Inc; April 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10322":"<p><b>Title</b> Everolimus / Venetoclax</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Venetoclax may increase the serum concentration of Everolimus. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Administer everolimus at least 6 hours before venetoclax when concomitant therapy is required.</p> \n<p><b>Discussion</b> Venetoclax US prescribing information states that use with certain P-glycoprotein substrates (digoxin, everolimus, and sirolimus) should be avoided if possible, based on in vitro inhibition studies that suggest a potential for venetoclax to inhibit intestinal P-glycoprotein-mediated efflux.<sup>1</sup> If concomitant therapy is required, prescribing information recommends that these P-glycoprotein substrates be administered at least 6 hours prior to venetoclax to minimize the potential for an interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Venclexta (venetoclax) [prescribing information]. North Chicago, IL: AbbVie Inc; April 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10323":"<p><b>Title</b> Venetoclax / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of Venetoclax. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Advise patients to avoid consuming grapefruit and grapefruit juice during venetoclax treatment.</p> \n<p><b>Discussion</b> Venetoclax US prescribing information states that grapefruit (and grapefruit products), Seville oranges, and star fruit should be avoided during venetoclax treatment because these fruits contain compounds that can inhibit CYP3A4.<sup>1</sup> CYP3A4 is the major enzyme known to metabolize venetoclax.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Venclexta (venetoclax) [prescribing information]. North Chicago, IL: AbbVie Inc; April 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10324":"<p><b>Title</b> Venetoclax / Star Fruit</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Star Fruit may increase the serum concentration of Venetoclax. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Advise patients to avoid consuming star fruit and star fruit juice during venetoclax treatment.</p> \n<p><b>Discussion</b> Venetoclax US prescribing information states that grapefruit (and grapefruit products), Seville oranges, and star fruit should be avoided during venetoclax treatment because these fruits contain compounds that can inhibit CYP3A4.<sup>1</sup> CYP3A4 is the major enzyme known to metabolize venetoclax.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Venclexta (venetoclax) [prescribing information]. North Chicago, IL: AbbVie Inc; April 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10325":"<p><b>Title</b> Venetoclax / Bitter Orange</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Bitter Orange may increase the serum concentration of Venetoclax. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Advise patients to avoid consuming Seville oranges and Seville orange juice during venetoclax treatment.</p> \n<p><b>Discussion</b> Venetoclax US prescribing information states that grapefruit (and grapefruit products), Seville oranges, and star fruit should be avoided during venetoclax treatment because these fruits contain compounds that can inhibit CYP3A4.<sup>1</sup> CYP3A4 is the major enzyme known to metabolize venetoclax.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Venclexta (venetoclax) [prescribing information]. North Chicago, IL: AbbVie Inc; April 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10326":"<p><b>Title</b> Sirolimus / Venetoclax</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Venetoclax may increase the serum concentration of Sirolimus. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Administer sirolimus at least 6 hours before venetoclax when concomitant therapy is required.</p> \n<p><b>Discussion</b> Venetoclax US prescribing information states that use with certain P-glycoprotein substrates (digoxin, everolimus, and sirolimus) should be avoided if possible, based on in vitro inhibition studies that suggest a potential for venetoclax to inhibit intestinal P-glycoprotein-mediated efflux.<sup>1</sup> If concomitant therapy is required, prescribing information recommends that these P-glycoprotein substrates be administered at least 6 hours prior to venetoclax to minimize the potential for an interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Venclexta (venetoclax) [prescribing information]. North Chicago, IL: AbbVie Inc; April 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10327":"<p><b>Title</b> Lomustine / CarBAMazepine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Canadian labeling recommends avoiding this combination while US labeling does not mention this potential interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CarBAMazepine may diminish the therapeutic effect of Lomustine. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for decreased lomustine effectiveness if combined with carbamazepine. US prescribing information does not mention this potential interaction while Canadian labeling recommends avoidance of this combination.</p> \n<p><b>Discussion</b> A retrospective analysis of glioblastoma patients treated with radiation and chemotherapy (primarily lomustine) reported that patients who had received enzyme-inducing antiepileptic drugs (phenytoin, carbamazepine, or both) had a reduced survival rate compared with patients who received non-enzyme-inducing antiepileptic drugs (primarily valproic acid) (10.8 months vs 13.7 months; <i>P</i> = 0.016).<sup>1</sup> The survival rate was not statistically lower for patients who received enzyme inducing antiepileptic drugs when compared with patients who did not receive antiepileptic drug therapy (10.8 months vs 11.6 months). Hematologic toxicities were greater among patients who received non-enzyme-inducing antiepileptic drug therapy compared with patients who received enzyme-inducing antiepileptic drug therapy.<sup>1</sup><br><br>Whether the observed difference in survival rate was due to decreased lomustine efficacy when combined with enzyme-inducing antiepileptic drugs, increased lomustine efficacy when combined with valproic acid, or unmeasured differences between groups is unknown. <br><br>The Canadian lomustine product monograph states that concomitant use with enzyme-inducing antiepileptic drugs should be avoided due to the potential for decreased lomustine efficacy.<sup>2</sup> The US lomustine prescribing information does not warn of this potential interaction.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Oberndorfer S, Piribauer M, Marosi C, Lahrmann H, Hitzenberger P, Grisold W. P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. <i>J Neurooncol</i>. 2005;72(3):255-260. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15937649\">[PubMed 15937649]</a></p>\n<p>2. CeeNU (lomustine-CCNU) [product monograph]. Montreal, Canada: Bristol-Myers Squibb Canada; February 2016.</p>\n<p>3. Gleostine (lomustine) [prescribing information]. Miami, FL: NextSource Biotechnology LLC; January 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10328":"<p><b>Title</b> Lomustine / Fosphenytoin-Phenytoin</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Canadian labeling recommends avoiding this combination while US labeling does not mention this potential interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosphenytoin-Phenytoin may diminish the therapeutic effect of Lomustine. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for decreased lomustine effectiveness if combined with fosphenytoin or phenytoin. US prescribing information does not mention this potential interaction while Canadian labeling recommends avoidance of this combination.</p>\n<div>\n <p><b>Fosphenytoin-Phenytoin Interacting Members</b> Fosphenytoin, Phenytoin</p>\n</div> \n<p><b>Discussion</b> A retrospective analysis of glioblastoma patients treated with radiation and chemotherapy (primarily lomustine) reported that patients who had received enzyme-inducing antiepileptic drugs (phenytoin, carbamazepine, or both) had a reduced survival rate compared with patients who received non-enzyme-inducing antiepileptic drugs (primarily valproic acid) (10.8 months vs 13.7 months; <i>P</i> = 0.016).<sup>1</sup> The survival rate was not statistically lower for patients who received enzyme inducing antiepileptic drugs when compared with patients who did not receive antiepileptic drug therapy (10.8 months vs 11.6 months). Hematologic toxicities were greater among patients who received non-enzyme-inducing antiepileptic drug therapy compared with patients who received enzyme-inducing antiepileptic drug therapy.<sup>1</sup><br><br>Whether the observed difference in survival rate was due to decreased lomustine efficacy when combined with enzyme-inducing antiepileptic drugs, increased lomustine efficacy when combined with valproic acid, or unmeasured differences between groups is unknown. <br><br>The Canadian lomustine product monograph states that concomitant use with enzyme-inducing antiepileptic drugs should be avoided due to the potential for decreased lomustine efficacy.<sup>2</sup> The US lomustine prescribing information does not warn of this potential interaction.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Oberndorfer S, Piribauer M, Marosi C, Lahrmann H, Hitzenberger P, Grisold W. P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. <i>J Neurooncol</i>. 2005;72(3):255-260. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15937649\">[PubMed 15937649]</a></p>\n<p>2. CeeNU (lomustine-CCNU) [product monograph]. Montreal, Canada: Bristol-Myers Squibb Canada; February 2016.</p>\n<p>3. Gleostine (lomustine) [prescribing information]. Miami, FL: NextSource Biotechnology LLC; January 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10329":"<p><b>Title</b> Lomustine / Valproate Products</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Canadian labeling recommends monitoring for increased lomustine toxicities with this combination while US labeling does not mention this potential interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Valproate Products may enhance the adverse/toxic effect of Lomustine. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> The lomustine US prescribing information does not mention this potential interaction while Canadian labeling recommends monitoring for increased lomustine toxicities if combined with valproate products.</p>\n<div>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> A retrospective analysis of glioblastoma patients treated with radiation and chemotherapy (primarily lomustine) reported that patients who had received enzyme-inducing antiepileptic drugs (phenytoin, carbamazepine, or both) had a reduced survival rate compared with patients who received non-enzyme-inducing antiepileptic drugs (primarily valproic acid) (10.8 months vs 13.7 months; <i>P</i> = 0.016).<sup>1</sup> The survival rate was not statistically lower for patients who received enzyme inducing antiepileptic drugs when compared with patients who did not receive antiepileptic drug therapy (10.8 months vs 11.6 months). Hematologic toxicities were greater among patients who received non-enzyme-inducing antiepileptic drug therapy compared with patients who received enzyme-inducing antiepileptic drug therapy.<sup>1</sup><br><br>Whether the observed difference in survival rate was due to decreased lomustine efficacy when combined with enzyme-inducing antiepileptic drugs, increased lomustine efficacy when combined with valproic acid, or unmeasured differences between groups is unknown. <br><br>The Canadian lomustine product monograph states that coadministration of valproate products and lomustine may decrease lomustine metabolism and increase toxicities.<sup>2</sup> The US lomustine prescribing information does not warn of this potential interaction.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Oberndorfer S, Piribauer M, Marosi C, Lahrmann H, Hitzenberger P, Grisold W. P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. <i>J Neurooncol</i>. 2005;72(3):255-260. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15937649\">[PubMed 15937649]</a></p>\n<p>2. CeeNU (lomustine-CCNU) [product monograph]. Montreal, Canada: Bristol-Myers Squibb Canada; February 2016.</p>\n<p>3. Gleostine (lomustine) [prescribing information]. Miami, FL: NextSource Biotechnology LLC; January 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10330":"<p><b>Title</b> Vaccines (Live) / Venetoclax</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Venetoclax may enhance the adverse/toxic effect of Vaccines (Live). Venetoclax may diminish the therapeutic effect of Vaccines (Live). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid use of live, attenuated vaccines before, during, or after (prior to B-cell recovery) venetoclax treatment.</p>\n<div>\n <p><b>Vaccines (Live) Interacting Members</b> Adenovirus (Types 4, 7) Vaccine, BCG Vaccine (Immunization), Cholera Vaccine, Influenza Virus Vaccine (Live/Attenuated), Japanese Encephalitis Virus Vaccine (Live/Attenuated), Measles, Mumps, and Rubella Virus Vaccine, Measles, Mumps, Rubella, and Varicella Virus Vaccine, Poliovirus Vaccine (Live/Bivalent/Oral), Poliovirus Vaccine (Live/Trivalent/Oral), Rotavirus Vaccine, Smallpox Vaccine Live, Typhoid Vaccine, Varicella Virus Vaccine, Yellow Fever Vaccine, Zoster Vaccine (Live/Attenuated)</p>\n</div> \n<p><b>Discussion</b> Venetoclax US prescribing information states that live vaccines should be avoided before, during, or after (prior to B-cell recovery) venetoclax treatment, as live vaccines may not be safe or effective during these times.<sup>1</sup> Venetoclax is used in patients expected to have compromised immune function, and is likely to further suppress immunity around the time of treatment.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Venclexta (venetoclax) [prescribing information]. North Chicago, IL: AbbVie Inc; April 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10331":"<p><b>Title</b> Vaccines (Inactivated) / Venetoclax</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Venetoclax may diminish the therapeutic effect of Vaccines (Inactivated). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Advise patients that vaccination may be less effective during venetoclax treatment.</p>\n<div>\n <p><b>Vaccines (Inactivated) Interacting Members</b> Anthrax Vaccine Adsorbed, Diphtheria and Tetanus Toxoids, Diphtheria and Tetanus Toxoids, Acellular Pertussis, and Poliovirus Vaccine, Diphtheria and Tetanus Toxoids, Acellular Pertussis, Hepatitis B (Recombinant), Poliovirus (Inactivated), and Haemophilus influenzae B Conjugate (Adsorbed) Vaccine, Diphtheria and Tetanus Toxoids, Acellular Pertussis, Poliovirus and Haemophilus b Conjugate Vaccine, Diphtheria and Tetanus Toxoids, and Acellular Pertussis Vaccine, Diphtheria, Tetanus Toxoids, Acellular Pertussis, Hepatitis B (Recombinant), and Poliovirus (Inactivated) Vaccine, Haemophilus b Conjugate Vaccine, Hepatitis A Vaccine, Hepatitis B Vaccine (Recombinant [Adjuvanted]), Hepatitis B Vaccine (Recombinant), Influenza A Virus Vaccine (H5N1), Influenza Virus Vaccine (Inactivated), Japanese Encephalitis Virus Vaccine (Inactivated), Meningococcal (Groups A / C / Y and W-135) Diphtheria Conjugate Vaccine, Meningococcal Group B Vaccine, Meningococcal Group C-CRM197 Conjugate Vaccine, Meningococcal Polysaccharide (Groups A / C / Y and W-135) Tetanus Toxoid Conjugate Vaccine, Meningococcal Polysaccharide (Groups C and Y) and Haemophilus b Tetanus Toxoid Conjugate Vaccine, Meningococcal Polysaccharide Group C Tetanus Toxoid Conjugate Vaccine, Meningococcal Polysaccharide Vaccine (Groups A / C / Y and W-135), Papillomavirus (9-Valent) Vaccine (Human, Recombinant), Papillomavirus (Types 16, 18) Vaccine (Human, Recombinant), Papillomavirus (Types 6, 11, 16, 18) Vaccine (Human, Recombinant), Pneumococcal Conjugate Vaccine (10-Valent), Pneumococcal Conjugate Vaccine (13-Valent), Pneumococcal Conjugate Vaccine (7-Valent), Pneumococcal Polysaccharide Vaccine (23-Valent), Poliovirus Vaccine (Inactivated), Q Fever Vaccine, Rabies Vaccine, Tetanus Toxoid (Adsorbed), Tick-Borne Encephalitis Virus Vaccine (Inactivated), Travelers' Diarrhea and Cholera Vaccine, Typhoid and Hepatitis A Vaccine, Zoster Vaccine (Recombinant)</p>\n</div> \n<p><b>Discussion</b> Venetoclax US prescribing information states that patients should be advised that vaccination may be less effective during venetoclax treatment.<sup>1</sup> Venetoclax is used in patients expected to have compromised immune function, and is likely to further suppress immunity around the time of treatment.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Venclexta (venetoclax) [prescribing information]. North Chicago, IL: AbbVie Inc; April 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10332":"<p><b>Title</b> PAZOPanib / AtorvaSTATin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> AtorvaSTATin may enhance the hepatotoxic effect of PAZOPanib. AtorvaSTATin may increase the serum concentration of PAZOPanib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the use of atorvastatin in combination with pazopanib whenever possible.</p> \n<p><b>Discussion</b> Atorvastatin is both a potent P-glycoprotein (P-gp) inhibitor and HMG-CoA reductase inhibitor (“statin”). Pazopanib U.S. prescribing information states that its use with inhibitors of the P-gp (also known as ABCB1) and/or breast cancer resistance protein (BCRP, also known as ABCG2) efflux transporters should be avoided when possible, because such agents could theoretically increase pazopanib exposure.<sup>1</sup> Pazopanib is a substrate of P-gp and BCRP in vitro, although the significance of these transporters to pazopanib pharmacokinetic characteristics in humans is unknown. In one study carried out in mice, coadministration of a single intravenous dose of pazopanib with inhibitors of both of these transporters increased pazopanib brain exposure without affecting its plasma concentrations.<sup>2</sup> Inhibitors of one of these transporters given without an inhibitor of the other, in contrast, had no impact on brain or plasma pazopanib exposure.<br><br>Furthermore, the pazopanib prescribing information also reports that the incidence of elevated alanine aminotransferase (ALT) concentrations, an indicator of liver damage, was higher among patients receiving pazopanib plus simvastatin, another HMG-CoA reductase inhibitor, (27%, 11/41) than among patients receiving pazopanib without simvastatin (14%, 126/895).<sup>1</sup> The degree to which this apparent risk applies to other statins is unknown. The specific mechanism for this possible interaction is also uncertain. Both simvastatin (along with other statins) and pazopanib have some independent risk for causing elevated ALT concentrations and hepatotoxicity.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Votrient (pazopanib) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; September 2015.</p>\n<p>2. Minocha M, Khurana V, Qin B, Pal D, Mitra AK. Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib. <i>Int J Pharm</i>. 2012;436(1-2):127-134. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22688250\">[PubMed 22688250]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10333":"<p><b>Title</b> Fosphenytoin-Phenytoin / Sulthiame</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Sulthiame may increase the serum concentration of Fosphenytoin-Phenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> For patients receiving concurrent sulthiame and phenytoin, concentrations of phenytoin should be strictly monitored and the dose should be adjusted as appropriate, especially in patients with impaired renal function. Phenytoin dosage may need to be reduced with the addition of sulthiame.</p>\n<div>\n <p><b>Fosphenytoin-Phenytoin Interacting Members</b> Fosphenytoin, Phenytoin</p>\n</div> \n<p><b>Discussion</b> A review of 136 patients receiving phenytoin reported a higher incidence of phenytoin toxicity and higher phenytoin concentrations in those patients also receiving sulthiame.<sup>1</sup> Of the 20 patients receiving both sulthiame (100 to 800 mg/day) and phenytoin, 40% (8/20) were described as having phenytoin intoxication, as compared to only 13% (15/116) of those receiving phenytoin without sulthiame. Average phenytoin concentrations were also 74% higher in sulthiame recipients, despite similar average phenytoin doses.<br><br>Sulthiame labeling states that concurrent use of sulthiame with phenytoin may result in markedly elevated phenytoin concentrations and that this combination requires close monitoring and may require frequent phenytoin dose adjustments in order to maintain therapeutic phenytoin concentrations, particularly in those patients with impaired renal function.<sup>2,3</sup><br><br>Possible mechanisms for this interaction include inhibition of phenytoin hydroxylation by sulthiame or one of its metabolites,<sup>4,5,6</sup> and/or displacement of phenytoin from tissue/protein binding sites.<sup>7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Houghton GW, Richens A. Phenytoin intoxication induced by sulthiame in epileptic patients. <i>J Neurol Neurosurg Psychiatry</i>. 1974;37(3):275-281. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4151416\">[PubMed 4151416]</a></p>\n<p>2. Sulthiame (Ospolot) [summary of product characteristics]. Lane Cove West, Australia: Phebra Pty Ltd; Novemeber 2013.</p>\n<p>3. Sulthiame (Ospolot) [summary of product characteristics]. Hod Hasharon, Israel: Megapharm Ltd.</p>\n<p>4. Houghton GW, Richens A. Inhibition of phenytoin metabolism by sulthiame in epileptic patients. <i>Br J Clin Pharmacol</i>. 1974;1(1):59-66. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22454870\">[PubMed 22454870]</a></p>\n<p>5. Houghton GW, Richens A. Proceedings: Inhibition of phenytoin metabolism by sulthiame. <i>Br J Pharmacol</i>. 1973;49(1):157P-158P. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4150763\">[PubMed 4150763]</a></p>\n<p>6. Hansen JM, Kristensen M, Skovsted L. Sulthiame (Ospolot) as inhibitor of diphenylhydatoin metabolism. <i>Epilepsia</i>. 1968;9(1):17-22. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4386877\">[PubMed 4386877]</a></p>\n<p>7. Olesen OV, Jensen ON. Drug--interaction between sulthiame (Ospolot (R)) and phenytoin in the treatment of epilepsy. <i>Dan Med Bull</i>. 1969;16(5):154-158. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4392189\">[PubMed 4392189]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10334":"<p><b>Title</b> Sulthiame / Primidone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Primidone may enhance the adverse/toxic effect of Sulthiame. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely (especially in pediatric patients) for increased side effects such as dizziness, unstable gait, drowsiness, and psychotic reactions.</p> \n<p><b>Discussion</b> Sulthiamine labeling states concomitant use of sulthiame and primidone may lead to severe side effects, especially in children, including dizziness, uncertain gait, drowsiness, and psychotic reactions.<sup>1,2</sup> Patients on concurrent therapy (especially pediatric patients) should be monitored closely for increased side effects.<br><br>A possible mechanism for this interaction is additive adverse effects of primidone and sulthiame.<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sulthiame (Ospolot) [summary of product characteristics]. Lane Cove West, Australia: Phebra Pty Ltd; Novemeber 2013.</p>\n<p>2. Sulthiame (Ospolot) [summary of product characteristics]. Hod Hasharon, Israel: Megapharm Ltd.</p>\n<p>3. Primidone (Mysoline) [prescribing information]. Aliso Viejo, CA: Valeant Pharmaceuticals North America; July 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10335":"<p><b>Title</b> Alcohol (Ethyl) / Sulthiame</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Sulthiame may enhance the adverse/toxic effect of Alcohol (Ethyl). Specifically, concurrent use may result in a disulfiram-like reaction. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid consuming alcohol while taking sulthiame. Concurrent use may result in a strong and unpleasant systemic reaction that may include, though not be limited to headache, nausea, vomiting, tachycardia, hypotension, confusion, loss of consciousness, and seizures.</p> \n<p><b>Discussion</b> Sulthiame labeling recommends avoiding alcohol when on sulthiame therapy.<sup>1,2</sup> Sulthiame, a sulfonamide derivative, can theoretically cause a disulfiram-like reaction to alcohol. If taken together, patients may experience a strong and very unpleasant, although generally self-limiting, systemic reaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sulthiame (Ospolot) [summary of product characteristics]. Lane Cove West, Australia: Phebra Pty Ltd; Novemeber 2013.</p>\n<p>2. Sulthiame (Ospolot) [summary of product characteristics]. Hod Hasharon, Israel: Megapharm Ltd.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10336":"<p><b>Title</b> PHENobarbital / Sulthiame</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Sulthiame may enhance the adverse/toxic effect of PHENobarbital. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for evidence of phenobarbital adverse reactions, such as drowsiness, CNS excitation or depression, bradycardia, or nervousness.</p> \n<p><b>Discussion</b> According to the sulthiame Australian labeling, sulthiame may increase the serum concentration of phenobarbital.<sup>1</sup> However, a clinical study of 121 patients using phenobarbital with phenytoin, carbamazepine, and sulthiame demonstrated that sulthiame did not affect the serum concentration of phenobarbital, though it is unknown what percentage of these patients took sulthiame.<sup>2</sup><br><br>The mechanism of this interaction is currently unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sulthiame (Ospolot) [summary of product characteristics]. Lane Cove West, Australia: Phebra Pty Ltd; Novemeber 2013.</p>\n<p>2. Eadie MJ, Lander CM, Hooper WD, Tyrer JH. The effects of phenobarbitone dose on plasma phenobarbitone levels in epileptic patients. <i>Proc Aust Assoc Neurol</i>. 1976;13:89-96. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1029012\">[PubMed 1029012]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10337":"<p><b>Title</b> LamoTRIgine / Sulthiame</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Sulthiame may increase the serum concentration of LamoTRIgine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor lamotrigine response (and concentrations as appropriate) more closely when used together with sulthiame, and particularly following any initiation/discontinuation or dose adjustment of sulthiame.</p> \n<p><b>Discussion</b> According to sulthiame labeling, sulthiame may increase the serum concentration of lamotrigine.<sup>1,2</sup> Specific data concerning the magnitude or consistency of this reported interaction are not provided.<br><br>The mechanism of this potential interaction is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sulthiame (Ospolot) [summary of product characteristics]. Lane Cove West, Australia: Phebra Pty Ltd; Novemeber 2013.</p>\n<p>2. Sulthiame (Ospolot) [summary of product characteristics]. Hod Hasharon, Israel: Megapharm Ltd.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10338":"<p><b>Title</b> Sulthiame / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Sulthiame. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor sulthiame response closely for evidence of ineffective therapy when used together with carbamazepine, particularly in the interval following carbamazepine initiation or any increase in carbamazepine dose.</p> \n<p><b>Discussion</b> According to the sulthiame Australian labeling, carbamazepine may decrease the serum concentration of sulthiame.<sup>1</sup> Sulthiame concentrations were reportedly significantly lower among 41 patients using sulthiame (most at doses greater than 600 mg/day) together with carbamazepine than among patients receiving sulthiame together with valproic acid, though specific concentrations were not reported.<sup>2</sup> Of note, the authors were unable to compare the results of sulthiame monotherapy versus sulthiame coadministered with carbamazepine.<br><br>The suspected mechanism of this interaction is carbamazepine induction of sulthiame metabolism/elimination.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sulthiame (Ospolot) [summary of product characteristics]. Lane Cove West, Australia: Phebra Pty Ltd; Novemeber 2013.</p>\n<p>2. May TW, Korn-Merker E, Rambeck B, Boenigk HE. Pharmacokinetics of sulthiame in epileptic patients. <i>Ther Drug Monit</i>. 1994;16(3):251-257. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7916169\">[PubMed 7916169]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10345":"<p><b>Title</b> Reboxetine / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Reboxetine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor clinical response to reboxetine closely, and watch specifically for evidence of reduced reboxetine effectiveness, if reboxetine is used together with a strong inducer of CYP3A4. Reboxetine dose increases may be required.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> Reduced reboxetine concentrations have apparently been reported with concurrent use of the strong CYP3A4 inducers carbamazepine and phenobarbital.<sup>1,2,3</sup> As a result, the reboxetine labeling cautions that dose increases may be needed with any such concurrent use.<br><br>This interaction is likely the result of increased reboxetine CYP3A4-mediated metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Edronax (reboxetine) [summary of product characteristics]. Kent, United Kingdon: Pfizer Limited; October 2015.</p>\n<p>2. Edronax (reboxetine) [summary of product characteristics]. West Ryde, New South Wales, Australia: Pfizer Australia Pty Ltd; October 2012.</p>\n<p>3. Prolift (reboxetine) [summary of product characteristics]. Guarulhos, Sao Paulo, Brazil: Pfizer Ltda; October 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10346":"<p><b>Title</b> OATP1B1/SLCO1B1 Substrates / Gemfibrozil</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Gemfibrozil may increase the serum concentration of OATP1B1/SLCO1B1 Substrates. See separate drug interaction monographs for agents listed as exceptions. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients receiving gemfibrozil and SLCO1B1 substrates for evidence of increased SLCO1B1 substrate exposure (eg, evidence of substrate toxicity). Prodrug substrates may also have diminished efficacy.</p>\n<div>\n <p><b>OATP1B1/SLCO1B1 Substrates Interacting Members</b> Asunaprevir, Bosentan, Fexofenadine, Fimasartan, Glecaprevir and Pibrentasvir, Grazoprevir, Irinotecan (Conventional), Irinotecan (Liposomal), Letermovir, Methotrexate, Nateglinide, Olmesartan, RifAMPin, Simeprevir, Torsemide, Valsartan, Voxilaprevir<br><b>Exceptions</b> AtorvaSTATin, Eluxadoline, Ezetimibe, Fluvastatin, Pitavastatin, Pravastatin, Repaglinide, Rosuvastatin, Simvastatin</p>\n</div> \n<p><b>Discussion</b> Gemfibrozil US prescribing information states that its use in combination with substrates of the SLCO1B1 transporter (also often referred to as OATP1B1) may require substrate dose adjustments.<sup>1</sup> The suspected primary mechanism of this interaction is gemfibrozil inhibition of SLCO1B1-mediated hepatic substrate uptake. Interactions via this suspected mechanism have been documented with gemfibrozil use in combination with several SLCO1B1 substrates, including repaglinide, eluxadoline, and several HMG-CoA reductase inhibitors (eg, rosuvastatin, pravastatin).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lopid (gemfibrozil) [prescribing information]. New York, NY: Pfizer Inc; March 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10347":"<p><b>Title</b> Heparin / Antithrombin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antithrombin may enhance the anticoagulant effect of Heparin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Closely monitor patients receiving antithrombin and heparin for clinical (eg, easy bruising or bleeding) and laboratory (aPTT assays, at close intervals) evidence of excessive anticoagulation.</p> \n<p><b>Discussion</b> Antithrombin US prescribing information states that use in combination with heparin may enhance anticoagulant effects.<sup>1</sup> Patients receiving this combination should be closely monitored for clinical (eg, easy bruising or bleeding) and laboratory (aPTT assays, at close intervals) evidence of excessive anticoagulation. Heparin exerts its anticoagulant effects in part by potentiating antithrombin effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Atryn (antithrombin) [prescribing information]. Framingham, MA: Revo Biologics Inc; December 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10348":"<p><b>Title</b> Heparins (Low Molecular Weight) / Antithrombin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antithrombin may enhance the anticoagulant effect of Heparins (Low Molecular Weight). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Closely monitor patients receiving antithrombin and low molecular weight heparins for clinical (eg, easy bruising or bleeding) and laboratory (anti-factor Xa assays, at close intervals, where appropriate) evidence of excessive anticoagulation.</p>\n<div>\n <p><b>Heparins (Low Molecular Weight) Interacting Members</b> Bemiparin, Dalteparin, Enoxaparin, Nadroparin, Tinzaparin</p>\n</div> \n<p><b>Discussion</b> Antithrombin US prescribing information states that use in combination with low molecular weight heparins may enhance anticoagulant effects.<sup>1</sup> Patients receiving this combination should be closely monitored for clinical (eg, easy bruising or bleeding) and laboratory (anti-factor Xa assays, at close intervals, where appropriate) evidence of excessive anticoagulation. Low molecular weight heparins exert their anticoagulant effects in part by potentiating antithrombin effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Atryn (antithrombin) [prescribing information]. Framingham, MA: Revo Biologics Inc; December 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10349":"<p><b>Title</b> Serotonin Modulators / Methylene Blue</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Methylene Blue may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of serotonin modulators and methylene blue. Discontinue serotonin modulators 4 to 5 half-lives prior to the administration of methylene blue. In emergency situations, the availability of alternative agents and interventions should be considered. If the benefit of methylene blue under such circumstances outweighs the risk of serotonin toxicity, consider discontinuation of the serotonin modulator and use of the lowest possible dose of methylene blue. Monitor for signs of CNS toxicity for 4 hours after the last dose of methylene blue.</p>\n<div>\n <p><b>Serotonin Modulators Interacting Members</b> 5-Hydroxytryptophan, Almotriptan, Amitriptyline, Amoxapine, Bromocriptine, BusPIRone, Cabergoline, Citalopram, ClomiPRAMINE, Cyclobenzaprine, Dapoxetine, Desipramine, Desvenlafaxine, Dextromethorphan, Dihydroergotamine, Dosulepin, Doxepin (Systemic), Doxepin (Topical), DULoxetine, Eletriptan, Ergoloid Mesylates, Ergonovine, Ergotamine, Escitalopram, FentaNYL, FLUoxetine, FluvoxaMINE, Frovatriptan, Imipramine, Isocarboxazid, Levomilnacipran, Linezolid, Lithium, Lofepramine, Lorcaserin, Maprotiline, Melitracen [INT], Meperidine, Methadone, Methylene Blue, Methylergonovine, Milnacipran, Mirtazapine, Moclobemide, Naratriptan, Nefazodone, Nortriptyline, PARoxetine, Pergolide, Phenelzine, Procarbazine, Promethazine, Protriptyline, Rasagiline, Rizatriptan, Safinamide, SAMe (S-adenosylmethionine), Selegiline, Sertraline, St John's Wort, SUMAtriptan, Tapentadol, Tedizolid, TraMADol, Tranylcypromine, TraZODone, Trimipramine, Tryptophan, Venlafaxine, Vilazodone, Vortioxetine, ZOLMitriptan<br><b>Exception</b> Nicergoline</p>\n</div> \n<p><b>Discussion</b> A number of case reports describe symptoms of serotonin toxicity/serotonin syndrome in patients receiving methylene blue during treatment with drugs that inhibit serotonin reuptake, including selective serotonin reuptake inhibitors,<sup>1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20</sup> tricyclic antidepressants (clomipramine),<sup>21,22</sup> serotonin/norepinephrine reuptake inhibitors (duloxetine, venlafaxine),<sup>11,19,23,24,25</sup> and mirtazipine.<sup>11</sup> Methylene blue doses as low as 1 mg/kg (single dose) have been implicated in these cases. In addition, one retrospective chart review identified a number of cases of postoperative neurologic sequelae in patients receiving methylene blue during treatment with serotonin reuptake inhibitors.<sup>26</sup><br><br>US and Canadian product labels for methylene blue state that concomitant use with serotonergic drugs should be avoided.<sup>27,28</sup> The Canadian product monograph also recommends that prescribers carefully consider discontinuation of serotonin reuptake inhibitors for a period of at least 4-5 half-lives prior to administration of methylene blue.<sup>27</sup> <br><br>The mechanism of this interaction has not been fully investigated, but in vitro data indicate that methylene blue inhibits monoamine oxidase (MAO), particularly the MAO-A isoform.<sup>29,30</sup> The combination of methylene blue with other serotonergic agents may lead to additive serotonergic effects and toxicities.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bach KK, Lindsay FW, Berg LS, Howard RS. Prolonged postoperative disorientation after methylene blue infusion during parathyroidectomy. <i>Anesth Analg</i>. 2004;99(5):1573-1574. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15502068\">[PubMed 15502068]</a></p>\n<p>2. Khavandi A, Whitaker J, Gonna H. Serotonin toxicity precipitated by concomitant use of citalopram and methylene blue. <i>Med J Aust</i>. 2008;189(9):534-535. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18976207\">[PubMed 18976207]</a></p>\n<p>3. Martindale SJ, Stedeford JC. Neurological sequelae following methylene blue injection for parathyroidectomy. <i>Anaesthesia</i>. 2003;58(10):1041-1042. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12969068\">[PubMed 12969068]</a></p>\n<p>4. Mathew S, Linhartova L, Raghuraman G. Hyperpyrexia and prolonged postoperative disorientation following methylene blue infusion during parathyroidectomy. <i>Anaesthesia</i>. 2006;61(6):580-583. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16704594\">[PubMed 16704594]</a></p>\n<p>5. Ng BK, Cameron AJ, Liang R, Rahman H. Serotonin syndrome following methylene blue infusion during parathyroidectomy: a case report and literature review. <i>Can J Anaesth</i>. 2008;55(1):36-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18166746\">[PubMed 18166746]</a></p>\n<p>6. Schwiebert C, Irving C, Gillman PK. Small doses of methylene blue, previously considered safe, can precipitate serotonin toxicity. <i>Anaesthesia</i>. 2009;64(8):924. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19604213\">[PubMed 19604213]</a></p>\n<p>7. Shanmugam G, Kent B, Alsaiwadi T, Baskett R. Serotonin syndrome following cardiac surgery. <i>Interact Cardiovasc Thorac Surg</i>. 2008;7(4):656-657. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18334520\">[PubMed 18334520]</a></p>\n<p>8. Pollack G, Pollack A, Delfiner J, Fernandez J. Parathyroid surgery and methylene blue: a review with guidelines for safe intraoperative use. <i>Laryngoscope</i>. 2009;119(10):1941-1946. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19598213\">[PubMed 19598213]</a></p>\n<p>9. Stanford BJ, Stanford SC. Postoperative delirium indicating an adverse drug interaction involving the selective serotonin reuptake inhibitor, paroxetine? <i>J Psychopharmacol</i>. 1999;13(3):313-317. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10512094\">[PubMed 10512094]</a></p>\n<p>10. Stanford SC, Stanford BJ, Gillman PK. Risk of severe serotonin toxicity following co-administration of methylene blue and serotonin reuptake inhibitors: an update on a case report of post-operative delirium. <i>J Psychopharmacol</i>. 2010;24(10):1433-1438. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19423610\">[PubMed 19423610]</a></p>\n<p>11. Sweet G, Standiford SB. Methylene-blue-associated encephalopathy. <i>J Am Coll Surg</i>. 2007;204(3):454-458. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17324781\">[PubMed 17324781]</a></p>\n<p>12. Nicolaou G, Lee D. Methylene blue-induced serotonin syndrome presenting with ocular clonus and failure of emergence from general anesthesia [published online March 4, 2016]. <i>Can J Anaesth</i>. doi: 10.1007/s12630-016-0622-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26943644\">[PubMed 26943644]</a></p>\n<p>13. Hencken L, To L, Ly N, Morgan JA. Serotonin syndrome following methylene blue administration for vasoplegic syndrome. <i>J Card Surg</i>. 2016;31(4):208-210. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26934199\">[PubMed 26934199]</a></p>\n<p>14. Martino EA, Winterton D, Nardelli P, et al. The blue coma: the role of methylene blue in unexplained coma after cardiac surgery. <i>J Cardiothorac Vasc Anesth</i>. 2016;30(2):423-427. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26703972\">[PubMed 26703972]</a></p>\n<p>15. Hanna ER, Clark JA. Serotonin syndrome after cardiopulmonary bypass: a case demonstrating the interaction between methylene blue and selective serotonin reuptake inhibitors. <i>A Case Rep</i>. 2014;2(9):113-114. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25611876\">[PubMed 25611876]</a></p>\n<p>16. Izdes S, Altintas ND, Soykut C. Serotonin syndrome caused by administration of methylene blue to a patient receiving selective serotonin reuptake inhibitors. <i>A Case Rep</i>. 2014;2(9):111-112. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25611875\">[PubMed 25611875]</a></p>\n<p>17. Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J. Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy. <i>J Clin Anesth</i>. 2015;27(3):247-251. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25499271\">[PubMed 25499271]</a></p>\n<p>18. McDonnell AM, Rybak I, Wadleigh M, Fisher DC. Suspected serotonin syndrome in a patient being treated with methylene blue for ifosfamide encephalopathy. <i>J Oncol Pharm Pract</i>. 2012;18(4):436-439. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22235061\">[PubMed 22235061]</a></p>\n<p>19. Majithia A, Stearns MP. Methylene blue toxicity following infusion to localize parathyroid adenoma. <i>J Laryngol Otol</i>. 2006;120(2):138-140. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16359577\">[PubMed 16359577]</a></p>\n<p>20. Grubb KJ, Kennedy JL, Bergin JD, Groves DS, Kern JA. The role of methylene blue in serotonin syndrome following cardiac transplantation: a case report and review of the literature. <i>J Thorac Cardiovasc Surg</i>. 2012;144(5):e113-e116. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22982035\">[PubMed 22982035]</a></p>\n<p>21. Heritier Barras AC, Walder B, Seeck M. Serotonin syndrome following methylene blue infusion: a rare complication of antidepressant therapy. <i>J Neurol Neurosurg Psychiatry</i>. 2010;81(12):1412-1413. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20547626\">[PubMed 20547626]</a></p>\n<p>22. Khan MA, North AP, Chadwick DR. Prolonged postoperative altered mental status after methylene blue infusion during parathyroidectomy: a case report and review of the literature. <i>Ann R Coll Surg Engl</i>. 2007;89(2):W9-W11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17346391\">[PubMed 17346391]</a></p>\n<p>23. Smith CJ, Wang D, Sgambelluri A, Kramer RS, Gagnon DJ. Serotonin syndrome following methylene blue administration during cardiothoracic surgery. <i>J Pharm Pract</i>. 2015;28(2):207-211. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25613051\">[PubMed 25613051]</a></p>\n<p>24. Top WM, Gillman PK, de Langen CJ, Kooy A. Fatal methylene blue associated serotonin toxicity. <i>Neth J Med</i>. 2014;72(3):179-181. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24846936\">[PubMed 24846936]</a></p>\n<p>25. Rowley M, Riutort K, Shapiro D, Casler J, Festic E, Freeman WD. Methylene blue-associated serotonin syndrome: a 'green' encephalopathy after parathyroidectomy. <i>Neurocrit Care</i>. 2009;11(1):88-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19263250\">[PubMed 19263250]</a></p>\n<p>26. Kartha SS, Chacko CE, Bumpous JM, Fleming M, Lentsch EJ, Flynn MB. Toxic metabolic encephalopathy after parathyroidectomy with methylene blue localization. <i>Otolaryngol Head Neck Surg</i>. 2006;135(5):765-768. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17071309\">[PubMed 17071309]</a></p>\n<p>27. Methylene blue [product monograph]. Toronto, Ontario, Canada: Alveda Pharmaceuticals Inc; September 2014.</p>\n<p>28. Provayblue (methylene blue) [prescribing information]. Shirley, NY: American Regent; April 2016. </p>\n<p>29. Ramsay RR, Dunford C, Gillman PK. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. <i>Br J Pharmacol</i>. 2007;152(6):946-951. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17721552\">[PubMed 17721552]</a></p>\n<p>30. Harvey BH, Duvenhage I, Viljoen F, et al. Role of monoamine oxidase, nitric oxide synthase and regional brain monoamines in the antidepressant-like effects of methylene blue and selected structural analogues. <i>Biochem Pharmacol</i>. 2010;80(10):1580-1591. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20699087\">[PubMed 20699087]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10350":"<p><b>Title</b> Desirudin / Anticoagulants</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Anticoagulants may enhance the anticoagulant effect of Desirudin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Discontinue treatment with other anticoagulants prior to desirudin initiation. If concomitant use cannot be avoided, monitor patients receiving these combinations closely for clinical and laboratory evidence of excessive anticoagulation.</p>\n<div>\n <p><b>Anticoagulants Interacting Members</b> Acenocoumarol, Antithrombin, Apixaban, Argatroban, Bemiparin, Betrixaban, Bivalirudin, Dabigatran Etexilate, Dalteparin, Danaparoid, Desirudin, Edoxaban, Enoxaparin, Fondaparinux, Heparin, Nadroparin, Phenindione, Protein C Concentrate (Human), Rivaroxaban, Tinzaparin, Warfarin</p>\n</div> \n<p><b>Discussion</b> Desirudin US prescribing information states that other agents that increase bleeding risk (including anticoagulants, dextran 40, systemic corticosteroids, and thrombolytic agents) should be discontinued prior to desirudin initiation.<sup>1</sup> Use of these agents in combination with desirudin is expected to increase the risk of hemorrhage.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Iprivask (desirudin) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; November 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10351":"<p><b>Title</b> Desirudin / Corticosteroids (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Corticosteroids (Systemic) may enhance the anticoagulant effect of Desirudin. More specifically, corticosteroids may increase hemorrhagic risk during desirudin treatment. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Discontinue treatment with systemic corticosteroids prior to desirudin initiation. If concomitant use cannot be avoided, monitor patients receiving these combinations closely for clinical and laboratory evidence of excessive anticoagulation.</p>\n<div>\n <p><b>Corticosteroids (Systemic) Interacting Members</b> Beclomethasone (Systemic), Betamethasone (Systemic), Corticotropin, Cortisone, Deflazacort, Dexamethasone (Systemic), Fludrocortisone, Hydrocortisone (Systemic), MethylPREDNISolone, PrednisoLONE (Systemic), PredniSONE, Triamcinolone (Systemic)</p>\n</div> \n<p><b>Discussion</b> Desirudin US prescribing information states that other agents that increase bleeding risk (including anticoagulants, dextran 40, systemic corticosteroids, and thrombolytic agents) should be discontinued prior to desirudin initiation.<sup>1</sup> Use of these agents in combination with desirudin is expected to increase the risk of hemorrhage.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Iprivask (desirudin) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; November 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10352":"<p><b>Title</b> Desirudin / Dextran</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Dextran may enhance the anticoagulant effect of Desirudin. More specifically, dextran may increase hemorrhagic risk during desirudin treatment. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Discontinue treatment with dextran prior to desirudin initiation when possible. If concomitant use cannot be avoided, monitor patients receiving these combinations closely for clinical and laboratory evidence of excessive anticoagulation.</p> \n<p><b>Discussion</b> Desirudin US prescribing information states that other agents that increase bleeding risk (including anticoagulants, dextran 40, systemic corticosteroids, and thrombolytic agents) should be discontinued prior to desirudin initiation.<sup>1</sup> Use of these agents in combination with desirudin is expected to increase the risk of hemorrhage.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Iprivask (desirudin) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; November 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10353":"<p><b>Title</b> Desirudin / Thrombolytic Agents</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Thrombolytic Agents may enhance the anticoagulant effect of Desirudin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Discontinue treatment with thrombolytic agents prior to desirudin initiation. If concomitant use cannot be avoided, monitor patients receiving these combinations closely for clinical and laboratory evidence of excessive anticoagulation.</p>\n<div>\n <p><b>Thrombolytic Agents Interacting Members</b> Alteplase, Defibrotide, Reteplase, Streptokinase, Tenecteplase, Urokinase</p>\n</div> \n<p><b>Discussion</b> Desirudin US prescribing information states that other agents that increase bleeding risk (including anticoagulants, dextran 40, systemic corticosteroids, and thrombolytic agents) should be discontinued prior to desirudin initiation.<sup>1</sup> Use of these agents in combination with desirudin is expected to increase the risk of hemorrhage.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Iprivask (desirudin) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; November 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10354":"<p><b>Title</b> Vitamin K Antagonists / Anticoagulants</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Laboratory/Diagnostic Result</b>: Combined use of these agents should be avoided once INR is established in the desired therapeutic range. Note that some anticoagulants (eg, argatroban, bivalirudin, apixaban, edoxaban, rivaroxaban) may affect INR and thus may be associated with different recommendations for INR monitoring during transition.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Anticoagulants may enhance the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Long-term coadministration of a vitamin K antagonist with another anticoagulant should generally be avoided due to an increased risk of serious bleeding. However, short-term coadministration of a vitamin K antagonist with a non-vitamin K antagonist anticoagulant is a common strategy to ensure adequate anticoagulation in the period between initiation (or re-initiation) of the vitamin K antagonist and establishment of its anticoagulant effects in the desired therapeutic range. When transitioning to warfarin from therapeutic anticoagulation with a parenteral anticoagulant such as heparin, low molecular weight heparin, or fondaparinux, the parenteral agent and warfarin are generally overlapped for at least 5 days and for at least 24 hours or 2 consecutive days after INR has reached the therapeutic range. Recommendations for transitioning from other anticoagulants such as dabigatran, rivaroxaban, apixaban, and edoxaban to warfarin vary by agent. Refer to the appropriate Lexi-Drugs full monograph content for detail. <br><br>During periods when a vitamin K antagonist and another anticoagulant are overlapped, closely monitor patients for clinical (eg, easy bruising or bleeding) and laboratory (eg, coagulation assay results) evidence of excessive anticoagulation. Promptly discontinue the non-vitamin K antagonist anticoagulant once the criteria for discontinuation have been met (eg, INR in therapeutic range). When transitioning from a vitamin K antagonist to another anticoagulant, overlap is generally avoided; the vitamin K antagonist is typically discontinued and the timing of initiation of the other anticoagulant is typically determined by INR testing.</p>\n<div>\n <p><b>Anticoagulants Interacting Members</b> Acenocoumarol, Antithrombin, Apixaban, Argatroban, Bemiparin, Betrixaban, Bivalirudin, Dabigatran Etexilate, Dalteparin, Danaparoid, Desirudin, Edoxaban, Enoxaparin, Fondaparinux, Heparin, Nadroparin, Phenindione, Protein C Concentrate (Human), Rivaroxaban, Tinzaparin, Warfarin</p>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n</div> \n<p><b>Discussion</b> The use of vitamin K antagonists in combination with other anticoagulants is expected to increase the risk of bleeding. Long-term coadministration should generally be avoided. However, short-term coadministration of a vitamin K antagonist with a non-vitamin K antagonist anticoagulant is a common strategy to ensure adequate anticoagulation in the period between initiation (or re-initiation) of the vitamin K antagonist and establishment of its anticoagulant effects in the desired therapeutic range.<sup>1,2</sup> Anticoagulant dosing and therapeutic goals during these transition periods vary by anticoagulant; refer to the appropriate Lexi-Drugs monograph content for full detail. For example, when transitioning to warfarin from therapeutic anticoagulation with a parenteral anticoagulant such as heparin, low molecular weight heparin, or fondaparinux, the parenteral agent and warfarin are generally overlapped for at least 5 days and for at least 24 hours or 2 consecutive days after INR has reached the desired therapeutic range.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Coumadin (warfarin) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; October 2015.</p>\n<p>2. Sintron (acenocoumarol) [product monograph]. Montreal, Quebec, Canada: Paladin Labs Inc; May 2009.</p>\n<p>3. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. <i>Chest</i>. 2016;149(2):315-352. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26867832\">[PubMed 26867832]</a></p>\n<p>4. Ageno W, Gallus AS, Wittkowsky A, et al; American College of Chest Physicians. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i>. 2012;141(2 Suppl):e44S-e88S. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22315269\">[PubMed 22315269]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10355":"<p><b>Title</b> Praziquantel / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of Praziquantel. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients for increased praziquantel effects/toxicity during concomitant use with grapefruit juice, especially when extended (eg, 14-day) praziquantel therapy is used.</p> \n<p><b>Discussion</b> Concurrent administration of oral praziquantel (1,800 mg) and grapefruit juice (250 mL; commercially-squeezed) in 9 subjects (crossover design with water) increased the praziquantel maximum serum concentration and AUC 1.62-fold and 1.90-fold, respectively.<sup>1</sup> The cause of these pharmacokinetic changes is likely related to reduced gut metabolism of praziquantel by CYP3A4, thus increasing the opportunity for absorption. The clinical implications of the increased praziquantel concentrations are unclear and have not been systematically evaluated.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Castro N, Jung H, Medina R, Gonzalez-Esquivel D, Lopez M, Sotelo J. Interaction between grapefruit juice and praziquantel in humans. <i>Antimicrob Agents Chemother</i>. 2002;46(5):1614-1616. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11959616\">[PubMed 11959616]</a></p>\n<p>2. Biltricide (praziquantel) [prescribing information]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc; February 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10356":"<p><b>Title</b> Praziquantel / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Praziquantel. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients for increased praziquantel effects/toxicity during concomitant use with strong CYP3A4 inhibitors, especially when extended (eg, 14-day) praziquantel therapy is used.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a study of 10 healthy volunteers, concurrent administration of ketoconazole (400 mg daily x 5 days) with praziquantel (20 mg/kg daily) was associated with a 93% increase in praziquantel AUC and a 102% increase in praziquantel maximum serum concentration.<sup>1</sup> <br><br>The mechanism of this interaction is likely ketoconazole inhibition of CYP3A4, an enzyme responsible for praziquantel metabolism.<sup>2</sup> The clinical implications of the increased praziquantel concentrations are unclear and have not been systematically evaluated.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ridtitid W, Ratsamemonthon K, Mahatthanatrakul W, Wongnawa M. Pharmacokinetic interaction between ketoconazole and praziquantel in healthy volunteers. <i>J Clin Pharm Ther</i>. 2007;32(6):585-593. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18021336\">[PubMed 18021336]</a></p>\n<p>2. Biltricide (praziquantel) [prescribing information]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc; February 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10357":"<p><b>Title</b> Ergonovine / Reverse Transcriptase Inhibitors (Non-Nucleoside)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Ergonovine. Specifically, this would be most likely with delavrdine, while other Non-Nucleoside Reverse Transcriptase Inhibitors may be more likely to decrease the concentration of Ergonovine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of ergonovine with non-nucleoside reverse transcriptase inhibitors is contraindicated according to the ergonovine product monograph.</p>\n<div>\n <p><b>Reverse Transcriptase Inhibitors (Non-Nucleoside) Interacting Members</b> Delavirdine, Efavirenz, Etravirine, Nevirapine, Rilpivirine</p>\n</div> \n<p><b>Discussion</b> The Canadian product monograph for ergonovine lists concurrent use of non-nucleoside reverse transcriptase inhibitors (NNRTIs) as a contraindication.<sup>1</sup> The specific reason for this is unclear, but the U.S. labeling for the related product methylergonovine warns about an interaction with the NNRTI delavirdine due to the potential for delavirdine to inhibit CYP3A4.<sup>2</sup><br><br>Although the U.S. methylergonovine label characterizes delavirdine as a potent CYP3A4 inhibitor, several clinical studies have shown that delavirdine increased the AUC of the CYP3A4 substrates indinavir and ritonavir by an average of 44% and 51%, respectively, which is more consistent with only weak CYP3A4 inhibition.<sup>3,4</sup> Additionally, none of the other NNRTIs have been shown to be even weak inhibitors of CYP3A4, with several acting instead as weak or moderate CYP3A4 inducers. As a result of these different CYP3A4 effects, it would be expected that concurrent delavirdine would result in an increase in ergonovine concentrations and effects, concurrent efavirenz or etravirine or nevirapine would decrease ergonovine concentrations and effects, and concurrent rilpivirine would have no significant impact on ergonovine concentrations or effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ergonovine Maleate Injection [product monograph]. Toronto, Ontario, Canada: Alveda Pharmaceuticals Inc.; May 2015.</p>\n<p>2. Methergine (methylergonovine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; June 2012.</p>\n<p>3. Shelton MJ, Hewitt RG, Adams J, Della-Coletta A, Cox S, Morse GD. Pharmacokinetics of ritonavir and delavirdine in human immunodeficiency virus-infected patients. <i>Antimicrob Agents Chemother</i>. 2003;47(5):1694-1699. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12709342\">[PubMed 12709342]</a></p>\n<p>4. Ferry JJ, Herman BD, Carel BJ, Carlson GF, Batts DH. Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers. <i>J Acquir Immune Defic Syndr Hum Retrovirol</i>. 1998;18(3):252-259. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9665503\">[PubMed 9665503]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10386":"<p><b>Title</b> Diclofenac (Systemic) / Resveratrol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Resveratrol may increase the serum concentration of Diclofenac (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased diclofenac effects/toxicities if combined with resveratrol.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 12 healthy volunteers, resveratrol (500 mg daily x 10 days) increased the diclofenac (100 mg single dose) AUC and maximum serum concentration 2.12-fold and 1.75-fold, respectively.<sup>1</sup><br><br>The mechanism of this interaction has not been fully investigated, but resveratrol inhibition of CYP2C9,<sup>2</sup> an enzyme responsible for diclofenac metabolism,<sup>3</sup> may play a role.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bedada SK, Yellu NR, Neerati P. Effect of resveratrol treatment on the pharmacokinetics of diclofenac in healthy human volunteers. <i>Phytother Res</i>. 2016;30(3):397-401. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26633237\">[PubMed 26633237]</a></p>\n<p>2. Chow HH, Garland LL, Hsu CH, et al. Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. <i>Cancer Prev Res (Phila)</i>. 2010;3(9):1168-1175. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20716633\">[PubMed 20716633]</a></p>\n<p>3. Arthrotec (diclofenac) [prescribing information]. New York, NY: Pfizer Inc; March 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10387":"<p><b>Title</b> QuiNIDine / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of QuiNIDine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of grapefruit juice and quinidine.</p> \n<p><b>Discussion</b> In a study of 6 healthy volunteers, grapefruit juice (250 mL twice daily x 4 days) for 4 days decreased quinidine (200 mg daily) total clearance 27% and increased the quinidine elimination half-life 19%.<sup>1</sup> In another study, grapefruit juice (240 mL single dose) delayed the quinidine (800 mg single oral dose) time to reach maximum serum concentrations by 106%, but no effect on the quinidine AUC.<sup>2</sup> There was a delay in reaching, and reduction in the magnitude of, the maximal effect of quinidine on the QTc interval.<sup>2</sup><br><br>Prescribing information for quinidine states that due to a potential delay in quinidine absorption as well as the potential for grapefruit juice to inhibit the metabolism of quinidine, concomitant use should be avoided.<sup>3</sup><br><br>Grapefruit juice inhibition of intestinal CYP3A4 is the likely mechanism for the observed increase in quinidine concentrations. The mechanism by which grapefruit juice may delay quinidine absorption is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Damkier P, Hansen LL, Brosen K. Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. <i>Br J Clin Pharmacol</i>. 1999;48(6):829-838. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10594487\">[PubMed 10594487]</a></p>\n<p>2. Min DI, Ku YM, Geraets DR, Lee H. Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers. <i>J Clin Pharmacol</i>. 1996;36(5):469-476. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8739026\">[PubMed 8739026]</a></p>\n<p>3. Quinidine gluconate [prescribing information]. Philadelphia, PA: Mutual Pharmaceutical Co; February 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10388":"<p><b>Title</b> Pimavanserin / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimavanserin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> A reduced pimavanserin dose of 17 mg once daily is recommended when pimavanserin is used in a patient who is also receiving a strong CYP3A4 inhibitor. Monitor patient response closely with any use of such a combination.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> The pimavanserin AUC and maximum serum concentration were an average of 3- and 1.5-fold higher, respectively, with concurrent use of the strong CYP3A4 inhibitor ketoconazole, according to the pimavanserin prescribing information.<sup>1</sup> A reduced pimavanserin dose is recommended if used together with a strong CYP3A4 inhibitor.<sup>1</sup><br><br>The likely mechanism for this interaction is inhibition of the CYP3A4-mediated metabolism of pimavanserin by ketoconazole, and it is expected that other strong CYP3A4 inhibitors would interact in a similar manner.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Nuplazid (pimavanserin) [prescribing information]. San Diego, CA: Acadia Pharmaceuticals Inc.; April 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10389":"<p><b>Title</b> Pimavanserin / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Pimavanserin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patient response closely for any evidence of reduced pimavanserin effectiveness with concurrent use of any strong CYP3A4 inducer. An increased pimavanserin dose may be required.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> The pimavanserin prescribing information cautions that concurrent use with a strong CYP3A4 inducer may result in reduced pimavanserin concentrations and diminished effectiveness, and that close monitoring of patient response is required and a pimavanserin dose increase may be needed.<sup>1</sup> Specific data regarding the use of such combinations are not available.<br><br>The likely mechanism for this predicted interaction is increased CYP3A4 metabolism of pimavanserin, which is a CYP3A4 substrate, by strong CYP3A4 inducers.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Nuplazid (pimavanserin) [prescribing information]. San Diego, CA: Acadia Pharmaceuticals Inc.; April 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10390":"<p><b>Title</b> Pimavanserin / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Pimavanserin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patient response closely for any evidence of reduced pimavanserin effectiveness with concurrent use of St John's Wort. An increased pimavanserin dose may be required.</p> \n<p><b>Discussion</b> The pimavanserin prescribing information cautions that concurrent use with a strong CYP3A4 inducer may result in reduced pimavanserin concentrations and diminished effectiveness, and that close monitoring of patient response is required and a pimavanserin dose increase may be needed.<sup>1</sup> St John's Wort (SJW) is specifically listed as an example of a strong CYP3A4 inducer, despite evidence suggesting SJW is more of a moderate, though highly variable, CYP3A4 inducer. Specific data regarding the use of this combination are not available.<br><br>The likely mechanism for this predicted interaction is increased CYP3A4 metabolism of pimavanserin, which is a CYP3A4 substrate, by SJW.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Nuplazid (pimavanserin) [prescribing information]. San Diego, CA: Acadia Pharmaceuticals Inc.; April 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10391":"<p><b>Title</b> Estriol (Systemic) / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Estriol (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased estriol effects (eg, decreased symptom relief, changes in uterine bleeding profile) if combined with a CYP3A4 inducer.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> Prescribing information for estriol states that no interactions between estriol and other medications have been reported in clinical practice.<sup>1,2</sup> However, concomitant use of other estrogen products, particularly oral contraceptives, with CYP3A4 inducers has resulted in increased estrogen metabolism and decreased efficacy.<sup>1,2</sup> Although data are limited, similar interactions between estriol and CYP3A4 inducers may occur.<sup>1,2</sup> Monitor patients for decreased estriol effects if these agents are combined.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ovestin (oestriol) tablets [product information]. Leonards NSW Australia: Aspen Pharmacare; September 2015.</p>\n<p>2. Ovestrion (estriol) tablets [prescribing information]. Sao Paulo Brazil: Schering-Plough Pharmaceutical Industry Ltda; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10392":"<p><b>Title</b> Estriol (Systemic) / CYP3A4 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Moderate) may decrease the serum concentration of Estriol (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased estriol effects (eg, decreased symptom relief, changes in uterine bleeding profile) if combined with a CYP3A4 inducer.</p>\n<div>\n <p><b>CYP3A4 Inducers (Moderate) Interacting Members</b> Bexarotene (Systemic), Bosentan, Dabrafenib, Efavirenz, Eslicarbazepine, Etravirine, Modafinil, Nafcillin, Rifapentine, St John's Wort</p>\n</div> \n<p><b>Discussion</b> Prescribing information for estriol states that no interactions between estriol and other medications have been reported in clinical practice.<sup>1,2</sup> However, concomitant use of other estrogen products, particularly oral contraceptives, with CYP3A4 inducers has resulted in increased estrogen metabolism and decreased efficacy.<sup>1,2</sup> Although data are limited, similar interactions between estriol and CYP3A4 inducers may occur.<sup>1,2</sup> Monitor patients for decreased estriol effects if these agents are combined.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ovestin (oestriol) tablets [product information]. Leonards NSW Australia: Aspen Pharmacare; September 2015.</p>\n<p>2. Ovestrion (estriol) tablets [prescribing information]. Sao Paulo Brazil: Schering-Plough Pharmaceutical Industry Ltda; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10393":"<p><b>Title</b> Estriol (Topical) / CYP3A4 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Moderate) may decrease the serum concentration of Estriol (Topical). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased estriol effects (eg, decreased symptom relief, changes in uterine bleeding profile) if combined with a CYP3A4 inducer.</p>\n<div>\n <p><b>CYP3A4 Inducers (Moderate) Interacting Members</b> Bexarotene (Systemic), Bosentan, Dabrafenib, Efavirenz, Eslicarbazepine, Etravirine, Modafinil, Nafcillin, Rifapentine, St John's Wort</p>\n</div> \n<p><b>Discussion</b> Prescribing information for estriol states that no interactions between estriol and other medications have been reported in clinical practice.<sup>1,2,3</sup> However, concomitant use of other estrogen products, particularly oral contraceptives, with CYP3A4 inducers has resulted in increased estrogen metabolism and decreased efficacy.<sup>1,2,3</sup> Although data are limited, similar interactions between estriol and CYP3A4 inducers may occur.<sup>1,2,3</sup> Monitor patients for decreased estriol effects if these agents are combined.<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ovestin [summary of product characteristics] Dublin, Ireland: Aspen Pharma Trading Limited; September 2014.</p>\n<p>2. Ovestin Ovula [prescibing information]. New South Wales, Australia: Aspen Pharmacare. Available at https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&amp;id=CP-2015-PI-02993-1&amp;d=2016042816114622483; Accessed December 2015.</p>\n<p>3. Ovestin [product information] New South Wales, Australia: Aspen Pharmacare. Available at https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&amp;id=CP-2014-PI-02257-1&amp;d=2016042816114622483; Accessed July 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10394":"<p><b>Title</b> Estriol (Topical) / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C:Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Estriol (Topical). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased estriol effects (eg, decreased symptom relief, changes in uterine bleeding profile) if combined with a CYP3A4 inducer.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> Prescribing information for estriol states that no interactions between estriol and other medications have been reported in clinical practice.<sup>1,2,3</sup> However, concomitant use of other estrogen products, particularly oral contraceptives, with CYP3A4 inducers has resulted in increased estrogen metabolism and decreased efficacy.<sup>1,2,3</sup> Although data are limited, similar interactions between estriol and CYP3A4 inducers may occur.<sup>1,2,3</sup> Monitor patients for decreased estriol effects if these agents are combined.<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ovestin [summary of product characteristics] Dublin, Ireland: Aspen Pharma Trading Limited; September 2014.</p>\n<p>2. Ovestin Ovula [prescibing information]. New South Wales, Australia: Aspen Pharmacare. Available at https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&amp;id=CP-2015-PI-02993-1&amp;d=2016042816114622483; Accessed December 2015.</p>\n<p>3. Ovestin [product information] New South Wales, Australia: Aspen Pharmacare. Available at https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&amp;id=CP-2014-PI-02257-1&amp;d=2016042816114622483; Accessed July 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10395":"<p><b>Title</b> Estriol (Systemic) / Nevirapine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nevirapine may decrease the serum concentration of Estriol (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased estriol effects (eg, decreased symptom relief, changes in uterine bleeding profile) if combined with nevirapine.</p> \n<p><b>Discussion</b> Prescribing information for estriol states that no interactions between estriol and other medications have been reported in clinical practice.<sup>1,2</sup> However, concomitant use of other estrogen products, particularly oral contraceptives, with nevirapine has resulted in increased estrogen metabolism and decreased efficacy.<sup>1,2</sup> Although data are limited, similar interactions between estriol and nevirapine may occur.<sup>1,2</sup> Monitor patients for decreased estriol effects if these agents are combined.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ovestin (oestriol) tablets [product information]. Leonards NSW Australia: Aspen Pharmacare; September 2015.</p>\n<p>2. Ovestrion (estriol) tablets [prescribing information]. Sao Paulo Brazil: Schering-Plough Pharmaceutical Industry Ltda; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10396":"<p><b>Title</b> Estriol (Systemic) / Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ritonavir may decrease the serum concentration of Estriol (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased estriol effects (eg, decreased symptom relief, changes in uterine bleeding profile) if combined with ritonavir.</p> \n<p><b>Discussion</b> Prescribing information for estriol states that no interactions between estriol and other medications have been reported in clinical practice.<sup>1,2</sup> However, concomitant use of other estrogen products, particularly oral contraceptives, with ritonavir has resulted in increased estrogen metabolism and decreased efficacy.<sup>1,2</sup> Although data are limited, similar interactions between estriol and ritonavir may occur.<sup>1,2</sup> Monitor patients for decreased estriol effects if these agents are combined.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ovestin (oestriol) tablets [product information]. Leonards NSW Australia: Aspen Pharmacare; September 2015.</p>\n<p>2. Ovestrion (estriol) tablets [prescribing information]. Sao Paulo Brazil: Schering-Plough Pharmaceutical Industry Ltda; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10397":"<p><b>Title</b> Estriol (Systemic) / Nelfinavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nelfinavir may decrease the serum concentration of Estriol (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased estriol effects (eg, decreased symptom relief, changes in uterine bleeding profile) if combined with nelfinavir.</p> \n<p><b>Discussion</b> Prescribing information for estriol states that no interactions between estriol and other medications have been reported in clinical practice.<sup>1,2</sup> However, concomitant use of other estrogen products, particularly oral contraceptives, with nelfinavir has resulted in increased estrogen metabolism and decreased efficacy.<sup>1,2</sup> Although data are limited, similar interactions between estriol and nelfinavir may occur.<sup>1,2</sup> Monitor patients for decreased estriol effects if these agents are combined.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ovestin (oestriol) tablets [product information]. Leonards NSW Australia: Aspen Pharmacare; September 2015.</p>\n<p>2. Ovestrion (estriol) tablets [prescribing information]. Sao Paulo Brazil: Schering-Plough Pharmaceutical Industry Ltda; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10398":"<p><b>Title</b> Estriol (Topical) / Nevirapine</p> \n<p></p> \n<p><b>Risk Rating</b> C:Monitor therapy</p> \n<p><b>Summary</b> Nevirapine may decrease the serum concentration of Estriol (Topical). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased estriol effects (eg, decreased symptom relief, changes in uterine bleeding profile) if combined with nevirapine.</p> \n<p><b>Discussion</b> Prescribing information for estriol states that no interactions between estriol and other medications have been reported in clinical practice.<sup>1,2,3</sup> However, concomitant use of other estrogen products, particularly oral contraceptives, with nevirapine has resulted in increased estrogen metabolism and decreased efficacy.<sup>1,2,3</sup> Although data are limited, similar interactions between estriol and nevirapine may occur.<sup>1,2,3</sup> Monitor patients for decreased estriol effects if these agents are combined.<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ovestin [summary of product characteristics] Dublin, Ireland: Aspen Pharma Trading Limited; September 2014.</p>\n<p>2. Ovestin Ovula [prescibing information]. New South Wales, Australia: Aspen Pharmacare. Available at https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&amp;id=CP-2015-PI-02993-1&amp;d=2016042816114622483; Accessed December 2015.</p>\n<p>3. Ovestin [product information] New South Wales, Australia: Aspen Pharmacare. Available at https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&amp;id=CP-2014-PI-02257-1&amp;d=2016042816114622483; Accessed July 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10399":"<p><b>Title</b> Estriol (Topical) / Nelfinavir</p> \n<p></p> \n<p><b>Risk Rating</b> C:Monitor therapy</p> \n<p><b>Summary</b> Nelfinavir may decrease the serum concentration of Estriol (Topical). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased estriol effects (eg, decreased symptom relief, changes in uterine bleeding profile) if combined with nelfinavir.</p> \n<p><b>Discussion</b> Prescribing information for estriol states that no interactions between estriol and other medications have been reported in clinical practice.<sup>1,2,3</sup> However, concomitant use of other estrogen products, particularly oral contraceptives, with nelfinavir has resulted in increased estrogen metabolism and decreased efficacy.<sup>1,2,3</sup> Although data are limited, similar interactions between estriol and nelfinavir may occur.<sup>1,2,3</sup> Monitor patients for decreased estriol effects if these agents are combined.<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ovestin [summary of product characteristics] Dublin, Ireland: Aspen Pharma Trading Limited; September 2014.</p>\n<p>2. Ovestin Ovula [prescibing information]. New South Wales, Australia: Aspen Pharmacare. Available at https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&amp;id=CP-2015-PI-02993-1&amp;d=2016042816114622483; Accessed December 2015.</p>\n<p>3. Ovestin [product information] New South Wales, Australia: Aspen Pharmacare. Available at https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&amp;id=CP-2014-PI-02257-1&amp;d=2016042816114622483; Accessed July 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}